Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease.
Mayte Gil-CandelJuan José Gascón CánovasElena Urbieta SanzRosa Gómez EspínIsabel Nicolás de PradoCarles Iniesta-NavalónPublished in: Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva (2021)
less than half of patients had target infliximab levels during the induction period. Therapeutic drug monitoring during this period is related to the achievement of therapeutic levels of infliximab and may lead to a better clinical response in these patients.